Company: NIVFW
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001213900-25-079717
Chunk: 94

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-22
Form: DRS
Chunk 94
---
 in which NewGenIvf does business; |

| ● | the outcome of future tax audits, examinations, or administrative appeals; and |

| ● | limitations or adverse findings regarding its ability to do business in some jurisdictions. |

Any of these developments
could have an adverse effect on its results of operations.

NewGenIvf’s reported financial results may be adversely affected by changes in accounting principles generally accepted in the U.S.

A change in the U.S. accounting
principles could have a significant effect on NewGenIvf’s reported results of operations and could affect the reporting of transactions
already completed before the announcement of a change.The adoption of new or revised accounting principles may require it to make changes
to its systems, processes and control, which could have a significant effect on its reported financial results, cause unexpected financial
reporting fluctuations, retroactively affect previously reported results or require it to make costly changes to its operational processes
and accounting systems upon or following the adoption of these standards.

If NewGenIvf’s estimates or judgments relating to its critical accounting policies prove to be incorrect, its results of operations could be adversely affected.

The preparation of financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in
NewGenIvf’s consolidated financial statements and accompanying notes appearing elsewhere in this prospectus. NewGenIvf bases its
estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, as provided
in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations of NewGenIvf — Critical Accounting Policies, Judgments and Estimates.” The results of these estimates form the basis for making judgments about the
carrying values of assets, liabilities and equity, and the amount of revenue and expenses that are not readily apparent from other sources.
Significant estimates and judgments used in preparing NewGenIvf’s consolidated financial statements include those related to the
determination of fair value of its Class A Ordinary Shares and Warrants and revenue recognition relating to services rendered but for
which no claim has yet been reported, among other things. NewGenIvf’s results of operations may be adversely affected if its assumptions
change or if actual circumstances differ from those in its assumptions, which could cause its results of operations to fall below the
expectations of securities analysts and investors, resulting in a decline in the market price of its Class A Ordinary Shares and Warrants.

NewGenIvf is subject to anti-cor